Douglas S. Lehrer, MD

Associate Professor, Psychiatry
Summit Behavioral Health, 1101 Summit Rd, Cincinnati, OH 45237-2621


  • American Board of Psychiatry and Neurology: Psychiatry, 1993

Academic Interests

  • Phenomenology, pathophysiology, genetics and neuroimaging of schizophrenia-spectrum disorders
  • Forensic Psychiatry
  • Vitamin D

Representative Publications

Peer-Reviewed Articles (selected)

Lehrer DS, Christian BT, Mantil J, Murray AC, Buchsbaum BR, Oakes T, Byne W, Kemether EM, Buchsbaum MS.  Thalamic and prefrontal FDG uptake in never-medicated patients with schizophrenia. Am J Psychiatry 2005;162:931–8.

Christian BT, Lehrer DS, Shi B, Narayanan TK, Strohmeyer P, Buchsbaum MS, Mantil J.  Measuring dopamine neuromodulation in the thalamus: Using [F-18]fallypride PET to study dopamine release during a spatial attention task. NeuroImage 2006;31(1):139-52

Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi B, Mantil J, Kemether E, Oakes T, Mukherjee J.  D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr Res 2006;85(1-3):232-244

Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric Comorbidities and Schizophrenia. Schizophr Bull 2009;35(2):383-402

Mossman D, Bowen MD, Vanness DJ, Bienenfeld D, Correll T, Kay J, Klykylo WM, Lehrer DS. Quantifying the Accuracy of Forensic Examiners in the Absence of a “Gold Standard.” Law & Human Behavior 2010 Oct;34(5):402-17.

Lehrer DS, Christian BT, Kirbas C, Chiang M, Sidhu S, Short H, Wang B, Shi B, Chu K-W, Merrill B, Buchsbaum MS. 18F-Fallypride binding potential in patients with schizophrenia compared to healthy controls. Schizophrenia Research 2010;122(1-3):43-52

Pato MT, Sobell J, Medeiros H, Abbott C, Sklar B, Genomic Psychiatry Consortium, Buckley P, Bromet E, Escamilla M, Fanous A, Lehrer D, Macciardi F, Malaspina D, McCarroll S, Marder S, Morley C, Nicollini H, Perkins D, Purcell S, Rapaport M, Sklar P, Smoller J, Knowles JA, Pato CN. The Genomic Psychiatry Cohort: Partners in Discovery. Am J Med Genet Part B 2013;9999:1–7.

Hartz SM, Pato CN, Medeiros H, Cavazos-Rehg P, Sobell J, Knowles JA, Bierut LJ, Pato MT, Genomic Psychiatry Cohort Consortium (GPCC)*. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014;71(3):248-254

Lehrer DS, Lorenz J. Anosognosia in Schizophrenia: Hidden in Plain Sight. Innovations in Clinical Neuroscience. 2014;11(5-6):10-17.

Lehrer DS, Pato MT, Nahhas RW, Miller BJ, Malaspina D, Buckley PF, Sobell JL, Walsh-Messinger J, Genomic Psychiatry Cohort Consortium, Pato CN. Paternal age effect: Replication in schizophrenia with intriguing dissociation between bipolar with and without psychosis. Am J Med Genet B Neuropsychiatr Genet. 2015 Jul 16. doi: 10.1002/ajmg.b.32334. [Epub ahead of print]

Malaspina D, Walsh-Messinger J, Antonius D, Dracxler R, Rothman K, Puthota J, Gilman C, Feuerstein JL, Keefe D, Goetz D, Goetz RR, Buckley P, Lehrer DS, Pato M, Pato C, Genomic Psychiatry Cohort Consortium. Parental age effects on odor sensitivity in healthy subjects and schizophrenia patients. Am J Med Genet B Neuropsychiatr Genet B. 2015 Jul 29. doi: 10.1002/ajmg.b.32351. [Epub ahead of print]

Fontanella CA, Hurst MA, Lehrer DS, Campo JV. Benzodiazepine use and risk of mortality among schizophrenia patients: A retrospective longitudinal study. Journal of Clinical Psychiatry. [Accepted for publication]

Book Chapters (selected)

Hoffman RE, Lehrer DS, McGlashan TH. Alterations of Speech, Thought, Perception, and Self-experience. In: Tasman A, Kay J, Lieberman J, First MB, Riba MB (Eds.). Psychiatry, 4th edition.  John Wiley & Sons, Ltd., London, 2014.

Lehrer DS, Dougherty DD, Rauch SL. Brain Imaging in Psychiatry. In: Tasman A, Kay J, Lieberman J, First MB, Riba MB (Eds.). Psychiatry, 4th edition.  John Wiley & Sons, Ltd., London, 2014.

Education History: 

M.D., University of Cincinnati College of Medicine, 1987

Residency, Psychiatry, University of Cincinnati Hospital, 1987-1991

Mental Health Executive Leadership Program, Weatherhead School of Management, Case Western Reserve University, Cleveland, 1996-97


History of Psychiatry, Course director

Neurobiology of Schizophrenia

Summit Neuroscience Seminar, Director

Research statement: 

Current activities:

Genomic Psychiatry Cohort (GPC): Site PI, Wright State University. GPC is a multi-site, NIMH-funded effort to create an historically large, open-access repository of genetic material and clinical characterization for people with schizophrenia-bipolar spectrum disorders as well as controls. There are presently over 35,000 subjects within the cohort and we are actively enrolling new participants with emphasis on those with African ancestry.

Multimodal imaging in schizophrenia: I continue work with my colleague, Dr. Monte Buchsbaum (U.California, San Diego), to analyse and interpret a remarkable, locally-acquired dataset of 18-F fallypride PET, FDG PET, MRI (structural, functional, diffusion tensor), and clinical and neuropsychological measures from a cohort of over 30 people with medication-naive schizophrenia, plus matched controls.

Inquiries into treatment of severe mental disorders using Ohio Medicaid Claims data: I am working with colleagues at the Ohio State University and the Ohio Department of Mental Health & Addiction Services to address questions concerning care of severely disorder people. Our first paper which addressed excess mortality associated with benzodiazepine use in people with schizophrenia was just accepted for publication. Next projects will include inquires into putative antisuicidal effects of lithium salts, and then efficacy and safety of psychostimulants in people with schizophrenia.

Vitamin D: I am working with our chief internist at Summit Behavioral Healthcare on the safety of long-term vitamin D supplementation. We will later turn our efforts to efficacy studies.

Neurological changes in Cognitive Processing Therapy: This is an fMRI study of veterans, done in collaboration with partners at the Cincinnati VA Medical Center.

Prediction of Competency to Stand Trial: This study is being performed at Summit Behavioral Healthcare with colleagues at the University of Cincinnati College of Medicine Department of Psychiatry.


Chief Clinical Officer, Summit Behavioral Healthcare, Cincinnati

Consulting psychiatrist, First Episode Psychosis program, Greater Cincinnati Behavioral Healthcare

Is this you? Log in to update your profile.